For Q1 FY2026 (ended March 31, 2026), Zura Bio reported a net loss of $24.2 million, an operating loss of $25.5 million, and a diluted EPS of -$0.22. The company held $225.6 million in cash and had $101.5 million in equity as of the end of the quarter.
•Net loss of $24.2 million, 38.9% wider than Q1 FY2025.
•Operating loss of $25.5 million, 32.4% wider year-over-year.
•Diluted EPS of -$0.22, 15.8% worse than the prior year.
•Cash and cash equivalents of $225.6 million as of March 31, 2026.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Zura Bio Limited, a clinical-stage biotechnology company develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops Torudokimab (ZB-880), a fully human immunoglobulin G4 monoclonal antibody targeting interleukin-33 that has completed Phase 1 clinical studies
Crebankitug (ZB-168), a fully human immunoglobulin G1 monoclonal antibody targeting interleukin-7 receptor alpha that has completed Phase 1 clinical studies. Founded in 2022, Zura Bio is headquartered in Henderson, Nevada.
Zura Bio Limited is a clinical-stage biotechnology company focused on developing medicines for autoimmune and inflammatory disorders. Its pipeline includes Tibulizumab, a bispecific antibody that neutralizes both IL-17A and BAFF, currently in Phase 2 trials. The company also has Torudokimab (ZB-880), a monoclonal antibody targeting interleukin-33 that completed Phase 1 studies, and Crebankitug (ZB-168), a monoclonal antibody targeting interleukin-7 receptor alpha that also completed Phase 1 studies. These therapies aim to address conditions where the immune system attacks the body, such as rheumatoid arthritis or psoriasis.
Where is Zura Bio (ZURA) listed and in what currency?
Zura Bio Limited is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol ZURA. The trading currency is the US Dollar (USD), as the company is headquartered in the United States and its shares are traded on a US exchange. This listing provides investors with access to the company's stock within the US equity markets.
What sector and industry does Zura Bio (ZURA) operate in?
Zura Bio operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on researching and developing novel drugs, particularly for autoimmune and inflammatory disorders. Biotechnology firms like Zura Bio typically use biological processes and living organisms to create therapies, distinguishing them from traditional pharmaceutical companies that often rely on chemical synthesis.
Where is Zura Bio (ZURA) headquartered and what is its background?
Zura Bio Limited is headquartered in Henderson, Nevada, United States. The company was founded in 2022, making it a relatively young clinical-stage biotechnology firm. Its operations are primarily based in the US, where it develops its pipeline of antibody-based therapies for autoimmune and inflammatory diseases. The company's location in Nevada places it within a growing biotech hub, though its research and development activities may extend beyond its headquarters.